Spots Global Cancer Trial Database for Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia

Official Title: Phase I Study of Pomalidomide in Relapsed or Refractory Waldenstrom Macroglobulinemia

Study ID: NCT01198067

Conditions

Recurrent Waldenstrom Macroglobulinemia

Refractory Waldenstrom Macroglobulinemia

Interventions

Pomalidomide

Study Description

Brief Summary: This phase I trial studies the side effects and best dose of pomalidomide in treating patients with Waldenstrom macroglobulinemia that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Pomalidomide may stimulate the immune system in different ways and stop cancer cells from growing.

Detailed Description: PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of pomalidomide in patients with relapsed or refractory Waldenstrom macroglobulinemia. SECONDARY OBJECTIVES: I. To evaluate the safety and toxicity profile of pomalidomide in patients with relapsed or refractory Waldenstrom macroglobulinemia. II. To evaluate the efficacy of pomalidomide in patients with relapsed or refractory Waldenstrom macroglobulinemia. OUTLINE: This is a dose-escalation study. Patients receive pomalidomide orally (PO) on days 1-28 or 1-21. Courses repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months.